Literature DB >> 3170830

Gadolinium DTPA enhanced MR imaging of ACTH-secreting microadenomas of the pituitary gland.

J L Doppman1, J A Frank, A J Dwyer, E H Oldfield, D L Miller, L K Nieman, G P Chrousos, G B Cutler, D L Loriaux.   

Abstract

Gadolinium diethylenetriamine pentaacetic acid (DTPA) enhanced magnetic resonance imaging was performed in eight patients with Cushing disease and surgically proven pituitary microadenomas. A 1.5 T scanner was used with 3 mm contiguous slices. Short repetition times (TR), short echo times (TE), and long TR, long TE sequences were obtained before and serially after intravenous administration of Gd-DTPA. Three of eight (38%) microadenomas were undetectable both without and with Gd-DTPA: one post-Gd-DTPA scan was false positive on the side opposite the adenoma. Hemihypophysectomy based on a petrosal sinus adrenocorticotropic hormone (ACTH) gradient cured all three patients. Two microadenomas (25%) were visible as hypointense foci following Gd-DTPA but not on unenhanced scans. The remaining three microadenomas (38%) were seen before and after Gd-DTPA on T1-weighted images. In this small series of ACTH-producing microadenomas, one-third were seen on unenhanced 1.5 T scans, one-third were seen only after Gd-DTPA, and one-third were not imaged even with Gd-DTPA enhancement.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170830     DOI: 10.1097/00004728-198809010-00002

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  22 in total

Review 1.  Cushing's syndrome in children and adolescents: current diagnostic and therapeutic strategies.

Authors:  M A Magiakou; G P Chrousos
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 2.  Pituitary magnetic resonance imaging in Cushing's disease.

Authors:  Giovanni Vitale; Fabio Tortora; Roberto Baldelli; Francesco Cocchiara; Rosa Maria Paragliola; Emilia Sbardella; Chiara Simeoli; Ferdinando Caranci; Rosario Pivonello; Annamaria Colao
Journal:  Endocrine       Date:  2016-07-19       Impact factor: 3.633

3.  Contrast behavior between microadenoma and normal pituitary gland after gadolinium injection as a function of time at 1.5 T.

Authors:  T Stadnik; A Stevenaert; A Beckers; D Van Herzele; R Luypaert; T Buisseret; M Osteaux
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

Review 4.  State of art imaging of the pituitary tumors.

Authors:  Nicholas J Patronas; Chia-Ying Liu
Journal:  J Neurooncol       Date:  2013-12-17       Impact factor: 4.130

5.  Perils and pitfalls in the diagnosis of Cushing's syndrome.

Authors:  K C Loh; P A Fitzgerald; T R Miller; J B Tyrrell
Journal:  West J Med       Date:  1998-07

6.  Pituitary microadenomas. Does Gadolinium enhance their demonstration?

Authors:  P Macpherson; D M Hadley; E Teasdale; G Teasdale
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

7.  The effect of MR contrast medium dose on pituitary gland enhancement, microlesion enhancement and pituitary gland-to-lesion contrast conspicuity.

Authors:  Walter S Bartynski; John F Boardman; Stephen Z Grahovac
Journal:  Neuroradiology       Date:  2006-05-03       Impact factor: 2.804

8.  Increased abnormal pituitary findings on magnetic resonance in patients with male idiopathic hypogonadotrophic hypogonadism.

Authors:  S E Bolu; M Tasar; G Uçkaya; E Gönül; F Deniz; I C Ozdemir
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

9.  In vivo manganese MR imaging of calcium influx in spontaneous rat pituitary adenoma.

Authors:  D J Cross; J A Flexman; Y Anzai; T Sasaki; P M Treuting; K R Maravilla; S Minoshima
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-09       Impact factor: 3.825

10.  Displacement of the normal pituitary gland by sellar and juxtasellar tumours: surgical-MRI correlation and use in differential diagnosis.

Authors:  M Sumida; T Uozumi; M Yamanaka; K Mukada; K Arita; K Kurisu; H Satoh; F Ikawa
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.